Country for PR: United States
Contributor: PR Newswire New York
Wednesday, August 05 2020 - 23:13
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire-AsiaNet/ --

    -- Company working to ensure broad global access to COVID-19 vaccine 
candidate, following approval from regulators 

Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen 
Pharmaceutical Companies have entered into an agreement with the U.S. 
government for the large scale domestic manufacturing and delivery in the U.S. 
of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, 
Ad26.COV2.S, for use in the United States following approval or Emergency Use 
Authorization by the U.S. Food and Drug Administration (FDA). 

The Biomedical Advanced Research and Development Authority (BARDA) [ 
], part of the U.S. Department of Health and Human Services' Office of the 
Assistant Secretary for Preparedness and Response, in collaboration with the 
U.S. Department of Defense, is committing over $1 billion for this agreement. 
The vaccine will be provided at a global not-for-profit basis for emergency 
pandemic use. The U.S. government may also purchase an additional 200 million 
doses of Ad26.COV2.S under a subsequent agreement. 

"Johnson & Johnson's global team of experts has worked tirelessly alongside 
BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to 
stop the spread of COVID-19. We greatly appreciate the U.S. government's 
confidence in, and support for, our R&D platform and efforts and the 
scalability of our vaccine technology. We are scaling up production in the U.S. 
and worldwide to deliver a SARS-CoV-2 vaccine for emergency use," said Paul 
Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific 
Officer, Johnson & Johnson.

Johnson & Johnson's efforts to develop a SARS-CoV-2 vaccine have been 
undertaken pursuant to an ongoing research and development collaboration with 
BARDA and under the oversight of the FDA. Based on the positive preclinical 
data [ 
] recently published in the peer reviewed journal Nature [ 
], the Phase 1/2a first-in-human clinical trial of the vaccine candidate, 
Ad26.COV2.S, is underway in healthy volunteers in the United States and 

The Company is evaluating one- and two-dose regimens, in its clinical program 
and working diligently to ensure broad, global access to the vaccine following 
approval or authorization by regulators. Johnson & Johnson aims to meet its 
goal to supply more than one billion doses globally through the course of 2021, 
provided the vaccine is safe and effective. 

Johnson & Johnson's SARS-CoV-2 vaccine program leverages Janssen's AdVac(R) 
technology [ 
]. The same technology was used to develop Janssen's European 
Commission-approved Ebola vaccine and construct its HIV, RSV and Zika vaccine 
candidates. More than 90,000 individuals have been vaccinated to date using the 
Janssen AdVac(R)-based platform.

About Johnson & Johnson 
At Johnson & Johnson, we believe good health is the foundation of vibrant 
lives, thriving communities and forward progress. That's why for more than 130 
years, we have aimed to keep people well at every age and every stage of life. 
Today, as the world's largest and most broadly-based healthcare company, we are 
committed to using our reach and size for good. We strive to improve access and 
affordability, create healthier communities, and put a healthy mind, body and 
environment within reach of everyone, everywhere. We are blending our heart, 
science and ingenuity to profoundly change the trajectory of health for 
humanity. Learn more at Follow us at @JNJNews [ 

About the Janssen Pharmaceutical Companies 
At Janssen, we're creating a future where disease is a thing of the past. We're 
the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make 
that future a reality for patients everywhere by fighting sickness with 
science, improving access with ingenuity, and healing hopelessness with heart. 
We focus on areas of medicine where we can make the biggest difference: 
Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, 
Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at Follow us at @JanssenGlobal [ 

Notice to Investors Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the 
Private Securities Litigation Reform Act of 1995 regarding development of 
potential preventive and treatment regimens for COVID-19. The reader is 
cautioned not to rely on these forward-looking statements. These statements are 
based on current expectations of future events. If underlying assumptions prove 
inaccurate or known or unknown risks or uncertainties materialize, actual 
results could vary materially from the expectations and projections of Janssen 
Pharmaceuticals Inc., and/or Johnson & Johnson. Risks and uncertainties 
include, but are not limited to: challenges and uncertainties inherent in 
product research and development, including the uncertainty of clinical success 
and of obtaining regulatory approvals; uncertainty of commercial success; 
manufacturing difficulties and delays; competition, including technological 
advances, new products and patents attained by competitors; challenges to 
patents; product efficacy or safety concerns resulting in product recalls or 
regulatory action; changes in behavior and spending patterns of purchasers of 
health care products and services; changes to applicable laws and regulations, 
including global health care reforms; and trends toward health care cost 
containment. A further list and descriptions of these risks, uncertainties and 
other factors can be found in Johnson & Johnson's Annual Report on Form 10-K 
for the fiscal year ended December 29, 2019, including in the sections 
captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. 
Risk Factors," and in the company's most recently filed Quarterly Report on 
Form 10-Q, and the company's subsequent filings with the Securities and 
Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the 
Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any 
forward-looking statement as a result of new information or future events or 

Logo - 

SOURCE  Johnson & Johnson

CONTACT: Jake Sargent, +1 202-569-5086,, Seema Kumar, +1, Katie Buckley, +44 7900-655-261,, Investor Relations: Chris DelOrefice, +1 732-524-2955, 
Jennifer McIntyre, +1 732-524-3922